Alnylam Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030

Updated on 02/04/2023

Stock Rating
7
Price Target
$251.00
Consensus
Outperform
Upside
7.55%
Analysts
7
Stock Rating
7
Upside
7.55%
Analysts
7
Price Target
$251.00

Alnylam Pharmaceuticals Stock Forecast and Price Target

In recent months, seven notable analysts have provided yearlong price targets for Alnylam Pharmaceuticals, with the average target coming in at $251.00. If it were to be achieved, this would result in a potential upside of approximately 7.55 percent from the most recent closing price in February, 2023. The high end is $415.00, and the low is $143.00. Although you may not be interested in ALNY stock, you should still be aware of its competitors.

$251.00

7.55% Upside

Outperform
Outperform

Alnylam Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Alnylam Pharmaceuticals's Price has grown from $0.00 to $0.00 – a 100.00% increase. Next year, analysts are expecting Fair Value to reach $256.84 – an increase of 100.00%. Over the next eight years, the forecast is for Fair Value to grow by 100.00%.

2023 Fair Value Forecast
$256.84
2024 Fair Value Forecast
$285.59
2025 Fair Value Forecast
$317.54
2026 Fair Value Forecast
$353.08
2027 Fair Value Forecast
$392.58
2028 Fair Value Forecast
$436.52
2029 Fair Value Forecast
$485.36
2030 Fair Value Forecast
$539.67
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
LLY Stock Forecast Eli Lilly and Outperform 16
$339.08 $333.19 17.97%
NOVO B Stock Forecast Novo Nordisk A/S Outperform 10
kr967.50 kr937.82 0.78%
PFE Stock Forecast Pfizer Inc Outperform 3
$44.06 $53.97 19.50%
AMGN Stock Forecast Amgen Inc Hold 7
$245.17 $268.00 13.39%
SAN Stock Forecast Sanofi Outperform 10
91.12€ 108.44€ 20.72%

Alnylam Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Alnylam Pharmaceuticals's Revenue has grown from $219.75M to $844.29M – a 284.20% increase. Next year, analysts are expecting Revenue to reach $1.47B – an increase of 73.79%. Over the next eight years, the forecast is for Revenue to grow by 1046.69%.

2023 Rev Forecast
$1.47B
2024 Rev Forecast
$2.16B
2025 Rev Forecast
$2.80B
2026 Rev Forecast
$3.82B
2027 Rev Forecast
$5.27B
2028 Rev Forecast
$6.53B
2029 Rev Forecast
$8.30B
2030 Rev Forecast
$9.68B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
MRNA Stock Forecast Moderna Outperform 11
$173.25 $0.00 23.23%
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥4.07k ¥0.00 35.30%
BAYN Stock Forecast Bayer Outperform 7
56.68€ 74.54€ 33.20%

Alnylam Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030

2023 DPS Forecast
$0.00
2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
BMRN Stock Forecast BioMarin Pharmaceutical Outperform 10
$112.20 $115.45 6.95%
SRPT Stock Forecast Sarepta Therapeutics Outperform 6
$119.00 $139.65 27.73%
IONS Stock Forecast Ionis Pharmaceuticals Outperform 9
$40.92 $52.42 22.19%

Alnylam Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Alnylam Pharmaceuticals's Free Cash Flow has grown, rising from $-418.59M to $-712.05M – a growth of 70.11%. In the following year, the 8 analysts surveyed believe that Alnylam Pharmaceuticals's Free Cash Flow will decrease by 41.00%, reaching $-420.13M. According to professionals, by 2030, Alnylam Pharmaceuticals's Free Cash Flow will have decreased by 577.28%, falling down to $3.40B.

2023 FCF Forecast
$-420130000.00
2024 FCF Forecast
$0.06B
2025 FCF Forecast
$0.46B
2026 FCF Forecast
$0.98B
2027 FCF Forecast
$1.78B
2028 FCF Forecast
$2.44B
2029 FCF Forecast
$3.55B
2030 FCF Forecast
$3.40B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside
4516 Stock Forecast Nippon Shinyaku Outperform 18
¥7.07k ¥0.00 55.59%
DCPH Stock Forecast Deciphera Pharmaceuticals Hold 6
$17.03 $0.00 -41.28%
STOK Stock Forecast Stoke Therapeutics Buy 4
$9.44 $61.44 450.85%

Alnylam Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Alnylam Pharmaceuticals's Net Income has decreased from $-886.12M to $-852.82M – a 3.76% drop. For the following year, the 12 analysts predict that Alnylam Pharmaceuticals's Net Income will drop by 37.69%, reaching $-531.38M. In 2030, the professionals' prediction is that ALNY's Net Income will decrease by 587.77%, reaching $4.16B.

2023 NI Forecast
$-531380000.00
2024 NI Forecast
$0.12B
2025 NI Forecast
$0.63B
2026 NI Forecast
$1.23B
2027 NI Forecast
$2.33B
2028 NI Forecast
$2.84B
2029 NI Forecast
$3.73B
2030 NI Forecast
$4.16B

Alnylam Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Alnylam Pharmaceuticals's EBITDA has decreased from $-922.26M to $-661.09M – a 28.32% drop! The next year, 8 experts forecast that Alnylam Pharmaceuticals's EBITDA will decrease by 15.04%, reaching $-561.69M. In 2030, professionals predict that Alnylam Pharmaceuticals's EBITDA will decrease by 400.28%, reaching $1.99B.

2023 EBITDA Forecast
$-561690000.00
2024 EBITDA Forecast
$0.15B
2025 EBITDA Forecast
$0.46B
2026 EBITDA Forecast
$1.63B
2027 EBITDA Forecast
$3.42B
2028 EBITDA Forecast
$1.23B
2029 EBITDA Forecast
$1.45B
2030 EBITDA Forecast
$1.99B

Alnylam Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Alnylam Pharmaceuticals has seen a decline in its EBIT, from $-939.43M to $-708.65M – a 24.57% decrease. In the next year, analysts believe that EBIT will reach $-745.30M – an increase of 5.17%. By 2030, professionals believe that Alnylam Pharmaceuticals's EBIT will have decreased by 866.53%, falling to $5.43B.

2023 EBIT Forecast
$-745300000.00
2024 EBIT Forecast
$-447340000.00
2025 EBIT Forecast
$-6970000.00
2026 EBIT Forecast
$0.34B
2027 EBIT Forecast
$0.93B
2028 EBIT Forecast
$2.76B
2029 EBIT Forecast
$4.30B
2030 EBIT Forecast
$5.43B

Alnylam Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, Alnylam Pharmaceuticals's EPS has decreased from $-6.70 to $-6.14 – a 8.36% drop. Next year, analysts are expecting EPS to reach $-6.56 – an increase of 6.84%. In 2030, professionals predict that Alnylam Pharmaceuticals's EPS will decrease by 540.72%, to $27.06.

2023 EPS Forecast
$-6.56
2024 EPS Forecast
$-3.26
2025 EPS Forecast
$0.11
2026 EPS Forecast
$3.94
2027 EPS Forecast
$9.46
2028 EPS Forecast
$17.16
2029 EPS Forecast
$23.45
2030 EPS Forecast
$27.06